Shattuck Labs, Inc. (STTK)
Automate Your Wheel Strategy on STTK
With Tiblio's Option Bot, you can configure your own wheel strategy including STTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STTK
- Rev/Share 0.3747
- Book/Share 1.3261
- PB 0.7348
- Debt/Equity 0.0335
- CurrentRatio 9.0776
- ROIC -1.0724
- MktCap 46676878.0
- FreeCF/Share -1.1075
- PFCF -0.8269
- PE -0.7033
- Debt/Assets 0.0294
- DivYield 0
- ROE -0.7969
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | STTK | Leerink Partners | -- | Outperform | -- | $4 | March 17, 2025 |
| Downgrade | STTK | Citigroup | Buy | Neutral | $8 | $2 | Oct. 2, 2024 |
| Downgrade | STTK | Needham | Buy | Hold | -- | -- | Oct. 2, 2024 |
| Downgrade | STTK | H.C. Wainwright | Buy | Neutral | -- | -- | Oct. 1, 2024 |
News
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –
Read More
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, …
Read More
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.
Read More
About Shattuck Labs, Inc. (STTK)
- IPO Date 2020-10-09
- Website https://www.shattucklabs.com
- Industry Biotechnology
- CEO Dr. Taylor H. Schreiber M.D., Ph.D.
- Employees 44